What class is the BRIUMVI UBLITUXIMAB-XIIY 150 MG/6ML INJECTION FOR IV trademark registered in?

The BRIUMVI UBLITUXIMAB-XIIY 150 MG/6ML INJECTION FOR IV trademark is registered in Class 005 (Pharmaceuticals, medical & veterinary preparations).

What is the serial number for BRIUMVI UBLITUXIMAB-XIIY 150 MG/6ML INJECTION FOR IV?

The USPTO serial number for BRIUMVI UBLITUXIMAB-XIIY 150 MG/6ML INJECTION FOR IV is 97715574.

What is the registration number for BRIUMVI UBLITUXIMAB-XIIY 150 MG/6ML INJECTION FOR IV?

BRIUMVI UBLITUXIMAB-XIIY 150 MG/6ML INJECTION FOR IV is registered under USPTO registration number 7627245.

BRI

USPTO Trademark Record

REGISTERED

BRIUMVI UBLITUXIMAB-XIIY 150 MG/6ML INJECTION FOR IV

SN 97715574·Reg 7627245·Filed Dec 13, 2022

Owner TG THERAPEUTICS, INC.

Pharmaceuticals, medical and veterinary preparations; sanitary preparations for medical purposes; dietetic food and substances adapted for medical or veterinary purposes, food for babies; dietary supplements for human beings and animals; adhesive plasters, materials for dressings; material for filling teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.

BRIUMVI UBLITUXIMAB-XIIY 150 MG/6ML INJECTION FOR IV (Serial No. 97715574), Registration No. 7627245, is a registered US trademark filed on Dec 13, 2022 by TG THERAPEUTICS, INC.. This trademark covers Class 005 (Pharmaceuticals, medical & veterinary preparations).

early section 8: December 24, 2030

Mark Intelligence

BRIUMVI UBLITUXIMAB-XIIY 150 MG/6ML INJECTION FOR IV (Reg. #7627245) is a registered US trademark that has been protecting its owner, TG THERAPEUTICS, INC., since 2022. The mark covers Class 005 (Pharmaceuticals, medical & veterinary preparations). Goods and services include Pharmaceuticals, medical and veterinary preparations; sanitary preparations for medical purposes; dietetic food and subs.... The mark faced 1 opposition proceeding during prosecution.

FILED

Dec 13, 2022

SERIAL

97715574

REG#

7627245

REGISTERED

Dec 24, 2024

Owner

Applicant

TG THERAPEUTICS, INC.

Entity

Corporation

State

Address

2 Gansevoort Street, 9th Floor, New York, NY, 10014

Country

Attorney

NameMaury M. Tepper, III

Law firm

Maury M. Tepper, III TEPPER & EYSTER, PLLC

Address

3724 BENSON DR, RALEIGH, NC 27609, United States

Get pre-filing clearance

AI attorney analyzes your proposed mark against USPTO — Go/No-Go verdict, class-by-class risks, and strategy recommendations.

Run clearance

Filing Information

StatusREGISTERED

Filing DateDec 13, 2022

Serial Number97715574

Registration No.7627245

Registration DateDec 24, 2024

Status DateDec 24, 2024

Published for OppositionJul 11, 2023

Mark TypeDesign with words

Status DescriptionLive and registered

Filing Signals

FILED

2022

YEARS AGO

CLASSES

MADRID FILINGS

—

Opposed 1× during prosecution

Search 14M+ trademarks

Free USPTO lookups by name, owner, or serial number. No account needed.

Search now

Full Goods & Services

CLASSES

OFFICE

USPTO

COUNTRY

Class 005Pharmaceuticals, medical & veterinary preparations

US codes: 005, 006, 018, 044, 046, 051, 052

First use anywhere: Jun 12, 2023

First use in commerce: Jun 12, 2023

This description is as filed with the USPTO and defines the scope of trademark protection.

Status History

27 events

REGISTERED-PRINCIPAL REGISTER

Dec 24, 2024

REGISTERED-PRINCIPAL REGISTER

NOTICE OF REGISTRATION CONFIRMATION EMAILED

Dec 24, 2024

NOTICE OF REGISTRATION CONFIRMATION EMAILED

ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED

Dec 03, 2024

ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED

NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED

Dec 03, 2024

NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED

CASE ASSIGNED TO INTENT TO USE PARALEGAL

Nov 05, 2024

CASE ASSIGNED TO INTENT TO USE PARALEGAL

STATEMENT OF USE PROCESSING COMPLETE

Nov 05, 2024

STATEMENT OF USE PROCESSING COMPLETE

TEAS STATEMENT OF USE RECEIVED

Sep 04, 2024

TEAS STATEMENT OF USE RECEIVED

USE AMENDMENT FILED

Sep 04, 2024

USE AMENDMENT FILED

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

Mar 05, 2024

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

SOU TEAS EXTENSION RECEIVED

Mar 04, 2024

SOU TEAS EXTENSION RECEIVED

SOU EXTENSION 1 FILED

Mar 04, 2024

SOU EXTENSION 1 FILED

SOU EXTENSION 1 GRANTED

Mar 04, 2024

SOU EXTENSION 1 GRANTED

NOA E-MAILED - SOU REQUIRED FROM APPLICANT

Sep 05, 2023

NOA E-MAILED - SOU REQUIRED FROM APPLICANT

PUBLISHED FOR OPPOSITION

Jul 11, 2023

PUBLISHED FOR OPPOSITION

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

Jul 11, 2023

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

Jun 21, 2023

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

APPROVED FOR PUB - PRINCIPAL REGISTER

Jun 07, 2023

APPROVED FOR PUB - PRINCIPAL REGISTER

TEAS RESPONSE TO OFFICE ACTION RECEIVED

Jun 06, 2023

TEAS RESPONSE TO OFFICE ACTION RECEIVED

CORRESPONDENCE RECEIVED IN LAW OFFICE

Jun 06, 2023

CORRESPONDENCE RECEIVED IN LAW OFFICE

TEAS/EMAIL CORRESPONDENCE ENTERED

Jun 06, 2023

TEAS/EMAIL CORRESPONDENCE ENTERED

NON-FINAL ACTION WRITTEN

Mar 09, 2023

NON-FINAL ACTION WRITTEN

NON-FINAL ACTION E-MAILED

Mar 09, 2023

NON-FINAL ACTION E-MAILED

NOTIFICATION OF NON-FINAL ACTION E-MAILED

Mar 09, 2023

NOTIFICATION OF NON-FINAL ACTION E-MAILED

ASSIGNED TO EXAMINER

Mar 08, 2023

ASSIGNED TO EXAMINER

NOTICE OF DESIGN SEARCH CODE E-MAILED

Jan 11, 2023

NOTICE OF DESIGN SEARCH CODE E-MAILED

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

Jan 10, 2023

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

NEW APPLICATION ENTERED

Dec 16, 2022

NEW APPLICATION ENTERED

BRIUMVI UBLITUXIMAB-XIIY 150 MG/6ML INJECTION FOR IV

Get pre-filing clearance

Search 14M+ trademarks

Run a conflict check

Other Marks by TG THERAPEUTICS, INC.

Other Marks in Class 005 — Pharmaceuticals, medical & veterinary preparations

Other Marks by Maury M. Tepper, III

Resources

Company